
|Videos|July 10, 2018
Treatment Options for Relapsed/Refractory Solid Tumors in Pediatric and Young Adult Patients
Author(s)Ami V. Desai, MD, MSCE
Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.
Advertisement
Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.
Currently, Desai says the best treatment option for these patients is surgery. There are also a number of inhibitors for some gene fusions found in these types of malignancies, but not all patients are able to enroll in these studies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
3
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
4
How the Immune System Drives Nerve Growth in TNBC
5


































